Schroeder v. Hutchinson Regional Medical Center

District Court, D. Kansas·Decided June 29, 2022·No. 2:17-cv-02060·Unknown

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF KANSAS

UNITED STATS OF AMERICA ex rel. ) THOMAS SCHROEDER, ) ) Relator, ) ) vs. ) Case No. 17-2060-DDC-KGG ) MEDTRONIC, INC., et al., ) ) Defendants. ) )

MEMORANDUM & ORDER ON RELATOR’S MOTION TO COMPEL

NOW BEFORE THE COURT is Relator’s Motion to Compel (Doc. 130) seeking an Order requiring Defendant Medtronic to produce documents relating to annual sales of peripheral artery disease (“PAD”) devices over a period of 11 years (Doc. 130-1, at 2). Defendant Medtronic generally argues that Plaintiff has failed to establish the relevance of this information and that it is duplicative of information that should be sought from other entities, unduly burdensome, and disproportionate to the needs of the case. (Doc. 139.) After review of the parties’ submissions, the Court GRANTS Relator’s motion (Doc. 130). BACKGROUND I. General Background.

Relator Thomas Schroeder1 brought this qui tam action on behalf of the United States government (hereinafter “the United States” or “the government”) in January 2017. (Doc. 1.) The original Complaint was filed under seal and alleged

violations of the False Claim Act, 31 U.S.C. § 3729, et seq., against Defendants Medtronic, Plc (“Medtronic”) and Hutchinson Regional Hospital (“Hutchinson” or “Hospital”). (Doc. 1.) The False Claims Act (“FCA”) generally prohibits private parties from ‘knowingly’ submitting ‘a false or fraudulent claim’ for

reimbursement. 31 U.S.C. § 3729(a)(1)(A). The FCA imposes civil liability on “any person who . . . knowingly presents, or causes to be presented, a false or fraudulent claim for payment or approval” to the United States government. 31

U.S.C. §3729(a)(1)(A). Medtronic sells medical devices and overlaps to a degree with certain regions in which relator’s company operates, making Relator’s company and Medtronic competitors. (Doc. 26, at 21, 29.) Hutchinson is a nonprofit hospital

located in Kansas. (Id., at 4.) Both Relator’s company and Medtronic market their services to Hutchinson. (Id., at 30.)

1 Relator is a Regional Sales Manager for a company selling medical devices in Kansas and around the country. (Doc. 26 at 3.) Relator filed an Amended Complaint in September 2019 (Doc. 14) and a Second Amended Complaint in July 2020. (Docs. 24, 26.) A Third Amended

Complaint was filed in October 2021 after the District Court granted in part Medtronic’s Motion to Dismiss. (Docs. 67, 72.) This resulted in another Motion to Dismiss filed by Medtronic on November 9, 2021, which argued that Relators’

allegations of medically unnecessary procedure and off-label promotion fail to state a claim and should be dismissed with prejudice. (See generally Docs. 75, 76.) The undersigned Magistrate Judge recently granted Relator’s request to file an additional amened pleading to:

(i) add Covidien, L.P. – a corporate entity related to Medtronic – as a party defendant; (ii) add Wichita Radiological Group, P.A. as a party defendant; (iii) clarify the description of peripheral arterial disease (‘PAD’) devices set forth in ¶ 35 of the [operative Complaint]; (iv) include the sale of Medtronic coronary devices under Relator’s False Claims Act, 31 U.S.C. § 3729, et seq. (the ‘False Claims Act’ or ‘FCA’) and anti- kickback statute, 42 U.S.C. § 1320a-7b(b) (the ‘AKS’), claims; (v) provide additional allegations regarding medically unnecessary and off-label devices in PAD procedures at the Robert J. Dole Veterans Administration Medical Center (‘Dole VA’) and additional evidence of Medtronic’s promoting thereof; and (vi) correct typographical errors in ¶¶ 116 and 131 of the [operative Complaint] regarding dates.

(Doc. 113, at 1-2; Doc. 126.) Given the subsequent filing of Relator’s Fourth Amended Complaint (Doc. 127), the District Court recently found Defendant Medtronic’s Motion to Dismiss the Third Amended Complaint to be moot. (Doc. 131, text entry.)

II. Request No. 45. In the motion currently before the Court, Relator seeks an Order compelling Defendant Medtronic to produce documents responsive to Request No.

45, which seeks information on annual sales of peripheral vascular devices over a period of 11 years (Doc. 130-1, at 2). Medtronic objected that the request was overly broad, unduly burdensome and sought information that is irrelevant, not proportional to the needs of the case, and “not reasonably calculated to lead to the

discovery of admissible evidence … .”2 (Doc. 130-1, at 4-5.) Medtronic based the objections on the language of the Request as it seeks “any documents,” that are related to sales of peripheral vascular devices to customers of Medtronic that are entirely unrelated to the claims and defenses in this action, and to the extent it seeks documents relating to sales of peripheral vascular devices that are not the subject of allegations contained in the Third Amended Complaint.

2 The Court instructs Defendant that the Federal Rules of Civil Procedure abandoned the “not reasonably calculated standard” standard approximately seven years ago with the 2015 amendments to Rule 26(b). Federal courts now analyze whether the information requested is relevant and “proportional to the needs of the case.” Mayhew v. AngMar Medical Holdings, Inc., No. 18-2365-JWL-KGG, 2019 WL 5535243, at n.1, n.2 (D. Kan. Oct. 25, 2019) (citing Fed.R.Civ.P. 26(b)). See also Frick v. Henry Industries, Inc., 13-2490-JTM-GEB, 2016 WL 6966971, at *5 (D. Kan. Nov. 29, 2016). (Id.)3 The Court notes that, since the discovery responses were served, Relator has been allowed to file the Fourth Amended Complaint, as discussed above.

After various communications between the parties, Relator narrowed the scope of Request No. 45. According to Relator, “instead of requesting Medtronic’s annual PAD device sales to all ‘other customers,’ Relator agreed to limit the

request just to ‘other VA medical centers.’” (Doc. 130, at 3.) Relator subsequently agreed to limit the request from all “other customers” and all “other VA medical centers,” to a sampling of eleven (11) VA facilities out of seventy (70) for the relevant timeframe. (Id., at 4.) This offered limitation was rejected by

Medtronic. (Id.) Medtronic has indicated that, without waiving these objections, it was “conducting a reasonable search” and agreed to produce “non-privileged,

responsive documents that are currently in its possession, custody, or control sufficient to show the annual sales of the at-issue devices during the relevant time period to Dole VA and Hutchinson.” (Doc. 130-1, at 5.) ANALYSIS

I. Standards for Discovery.

3 Medtronic also objected “to the extent [the Request] seeks documents protected by the attorney-client privilege or work product doctrine.” (Doc. 130-1, at 5.) Medtronic is no longer asserting that the sales data is privileged. As such, this objection will not be addressed by the Court herein. Fed.R.Civ.P. 26

Free access — add to your briefcase to read the full text and ask questions with AI

Schroeder v. Hutchinson Regional Medical Center, (D. Kan. 2022).

Schroeder v. Hutchinson Regional Medical Center (Schroeder v. Hutchinson Regional Medical Center) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related